Biopharma
By
What Drives Novartis’ Pipeline Dominance Through 2030?
Novartis’ clinical pipeline exemplifies a “focus factory” strategy, ruthlessly prioritizing 30+ high-ROI NMEs across five core areas (immunology,…
Is CMS’s Block on Elevance MA Sign‑Ups a Turning Point for Payer Compliance?
The Centers for Medicare & Medicaid Services (CMS) has halted new Medicare Advantage enrollments for Elevance Health, freezing sign‑ups for…
Is Pierre Fabre’s US Cell‑Therapy Comeback Bid a Signal of Regulatory Reset for Rare Diseases?
Pierre Fabre is reviving its US cell‑therapy ambitions, seeking FDA re‑approval for Ebvallo after the agency initially rejected its submission.…
Is Roche’s $480M Bet Making South Korea Asia’s Next Biopharma Powerhouse?
Roche’s $480M Bet on South Korea Signals a Strategic Pivot to Asia’s AI–Oncology Powerhouse Roche has committed $480 million to…
Can Novartis AG’s $3 Billion AI-Driven Oncology Bet Redefine Precision Breast Cancer Treatment and Accelerate Next-Gen Drug Discovery?
Key Highlights: AI-Led Drug Discovery Accelerates Target Identification and ValidationNovartis AG’s acquisition of SNV4818 from Synnovation Therapeutics, Inc.…
How Will Emerging Drug Pricing Policies Reshape the Global Biopharma Industry in the Near and Long Term?
The global biopharmaceutical industry is entering a new policy-driven era as governments intensify efforts to control drug costs,…
